trending Market Intelligence /marketintelligence/en/news-insights/trending/_A2UpUpOMhXryeiS3OpAyQ2 content esgSubNav
In This List

Report: Takeda nears selling emerging market, western Europe drug portfolio

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Podcast

Street Talk Episode 87

Blog

A New Dawn for European Bank M&A Top 5 Trends

Blog

Insight Weekly: US banks' loan growth; record share buybacks; utility M&A outlook


Report: Takeda nears selling emerging market, western Europe drug portfolio

Takeda Pharmaceutical Co. Ltd. is nearing to sell its portfolio of over-the-counter and prescription drugs in emerging markets and western Europe in separate transactions, Bloomberg News reported, citing people familiar with the matter.

The assets, which may be sold to different buyers in Latin America, the Middle East, Africa, Russia and Asia in the coming weeks, could bring Takeda up to $3 billion, according to the report.

Bidders for the various assets, which could be sold by geography, include Swiss company Acino International AG, backed by private equity firms Nordic Capital and Avista Capital Holdings LP; and Cinven Ltd.- and Bain Capital LP-owned Stada Arzneimittel AG, the sources said.

Meanwhile, PE firms Advent International Corp., Apollo Global Management Inc. and Cerberus Capital Management LP are eyeing Takeda's over-the-counter and prescription drug portfolio in western Europe — a transaction that could value the assets at about €1 billion, the report noted.

In May, Brazil's EMS SA was reportedly in the lead to acquire Takeda's Latin America business, which sells vaccines, oncology, gastroenterology and over-the-counter products.

The Japanese drugmaker said in 2018 that it plans to sell about $10 billion in assets to reduce debt and simplify its portfolio after acquiring Shire PLC for £46 billion.